Industrial and materials companies (e.g. FedEx, UPS, Lockheed Martin, Boeing) that do large investments and large buying are the big winners from 100% expensing, evidenced by their membership in a '100% expensing coalition'; tech/software companies also benefit because software is included in the definition.

The bill loosens the corporate interest deduction limit from 30% of EBIT to 30% of EBITDA, a more generous standard that is less growth-oriented but important for utilities.

Like Obamacare's cuts that were enacted in 2009-11 but didn't kick in until 2013, the Medicaid changes won't take effect until 2028, so every healthcare problem will be blamed on this bill even though the actual cuts haven't yet occurred.

The big beautiful bill makes the expiring individual tax cuts permanent, eliminating a year-end fiscal cliff and removing second-half-of-year uncertainty for businesses, and notably patches the alternative minimum tax which would otherwise have added a $400 billion tax increase on January 1st.

Although the CBO says the bill increases the deficit by $3.4 trillion over 10 years, it also says Trump's tariffs will raise $2.8 trillion over 10 years, and with another ~$600 billion in newly added tariffs the gap is effectively bridged, so the two must be analyzed together — leaving the deficit roughly status quo at ~6.2-6.3% of GDP rather than the 9% claimed in the Moody's downgrade.

R&D expensing for research and development conducted in America benefits medtech, pharma, and biotech; the structure creates two distinct types of winners — sellers of goods who get sales and earnings, and buyers of goods who get to write them off.

The business tax cuts function as a 'tariff sterilization': by offsetting the price increases caused by tariffs, the bill prevents the tariffs from causing the recession they otherwise would have, making the combined package a sterilization rather than a pure stimulus.

States finance Medicaid by raising taxes to put more money into the system, which triggers more federal matching money; the bill caps these provider taxes (House at ~6%, Senate going to 3.5%), which will cause pain for states, but the changes don't take effect until 2028 — a presidential election year — and a ~$100 billion rural hospital stabilization fund cushions the impact.

The US has entered its first period of austerity in 30 years because interest cost relative to tax revenue is ~18%, above the ~14% threshold where austerity historically kicks in; extending existing tax cuts financed by new tariffs is itself a form of austerity, and the country is now moving into 'budget trench warfare' with recurring fiscal battles year after year.

The bill raises the debt ceiling by $5 trillion, and Treasury Secretary Bessent stated Treasury will take its time refilling the Treasury General Account rather than flooding the market with debt immediately, which has calmed fixed income markets regarding near-term issuance.

R&D expensing benefits a much broader set of companies — the Magnificent Seven tech companies, healthcare companies, and industrials/materials — while factory-building incentives could produce 'ghost factories' that employ no one, but the economy still benefits from riding the construction wave while they are being built.

Trump's tariffs are currently subtracting from growth and slowing the economy, having peaked at ~$700 billion on April 2nd before being reduced to ~$330 billion; Bessent's strategy of delaying tariffs to let fiscal policy sterilize them first has produced a far more optimal policy mix today than the bad mix of three or four months ago.

Drug companies like Vertex argue that price controls limit innovation in isolated, hard-to-treat areas (e.g. cystic fibrosis) where research is most needed, which is the policy rationale behind exempting orphan drugs from price controls.

The bill delivers Trump's campaign priorities — no/less tax on tips, overtime, seniors, and auto loan payments — amounting to over $100 billion of consumer aid arriving in Q1/early Q2 of next year at tax-filing time, which acts as a reload if the economy slows or an accelerant if it doesn't.

The bill cuts taxes by $4.5 trillion while cutting spending by $1.5 trillion, with the four spending-cut areas being renewable energy/IRA (over $500B), Medicaid (~$1T over 10 years, achieved by slowing growth not absolute cuts), food stamps (impacting consumer staples), and student loan reorganization (~$350B savings).

The bill makes 100% expensing of capital goods orders permanent, which feeds directly into non-residential capex and GDP; companies like John Deere and Caterpillar will use it as a sales tool ('buy this tractor now and write it off immediately').

The bill allows 100% immediate expensing of factory construction in America, effectively making a new factory ~30% cheaper by capturing the time value of money instead of depreciating over a 30-year life cycle, which neutralizes tariff-driven cost-prohibitiveness and is likely to trigger a building boom in data centers, factories, and LNG export terminals.

Student loan reorganization clamps down on Biden's SAVE program and income forgiveness and restructures the high-default Graduate PLUS program, saving the government money while pushing the system toward privatization, creating potential opportunity for private lenders like Sallie Mae.

Pharma and biotech stocks were eviscerated this year due to threatened most-favored-nation price controls and a 25% pharma tariff, but the bill plus Trump's decision to delay pharma tariffs 12-18 months (to encourage reshoring under 100% factory expensing), the exemption from IRA price controls for companies with two or more orphan drugs, and R&D expensing collectively make the sector more attractive after a massive derating.

The conceptual purpose of the Medicaid changes is to wipe out the $800 billion January cost increase via work requirements, twice-yearly income verification (saving over $100 billion), and reducing waste/fraud/abuse (~$250 billion), rather than absolute cuts.